OFEV® (Nintedanib) 150 microgram and 100 microgram packaging

OFEV®

OFEV®

Nintedanib

Product Overview

OFEV® is an anti-fibrotic medicine and contains the active ingredient nintedanib. It is used in adults for the treatment of idiopathic pulmonary fibrosis (IPF) and other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.1
OFEV® (Nintedanib) 150 microgram and 100 microgram packaging

Quick links

Quick links

Product Key Facts

Indications

In adults for the treatment of idiopathic pulmonary fibrosis (IPF) and other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype

Active ingredient

Nintedanib esilate

Legal category

Prescription only medicine

Doses and frequency

The recommended dose is 150 mg nintedanib twice daily administered approximately 12 hours apart

Route of administration

Oral

Pharmaceutical form

Soft capsule
 
 
Reference

1.

OFEV® 100 mg and 150 mg soft capsules Summary of Product Characteristics. Boehringer Ingelheim.

PC-GB-106291

March 2022

Reporting adverse events

Adverse events should be reported. Reporting form and information can be found atwww.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on0800 328 1627 (freephone).

Please be aware that this website contains promotional information about Boehringer Ingelheim medicines and services. Some of this may not be directly relevant to your scope of practice and it is your own decision whether you choose to view this information.